Skip to main content

Table 3 (A) Median of overall survival analysis in all metastatic and non-metastatic gastric cancer patients in the whole study. (B) Death percentage analysis in all metastatic and non-metastatic gastric cancer patients in the whole study

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

Group Metastatic Non-metastatic
Total number BCc1 (n = 33) Placebo (n = 30) BCc1 (n = 30) Placebo (n = 30)
(A) Median of overall survival analysis
Median (days) 174 62 529 345
Std. error 46.748 46.643 69.263 107.218
Median 95% CI (lower) 82.374 0.000 393.245 134.854
Median 95% CI (upper) 265.626 153.421 664.755 555.146
P-value for test of equality of survival distributions 0.04 0.05
HR
(BCc1/Placebo)
0.5 0.324
(B) Death percentage analysis
Death percentage 48.5% 63.3% 12.9% 29.6%
  1. Test of equality of survival distributions (for Bcc1 and placebo groups) assay with Log Rank (Mantel-Cox)